The biggest side effect of Ozempic is gastrointestinal distress, particularly nausea. It affects a large proportion of users and is the most common reason people struggle with or stop taking the medication. But Ozempic also carries several less common, more serious risks that are worth understanding before you start or while you’re on it.
Why Nausea Is So Common
Ozempic works by mimicking a gut hormone called GLP-1, which signals your brain to feel full and slows how quickly food leaves your stomach. That slower emptying is a feature, not a bug: it’s part of how the drug reduces appetite and controls blood sugar. But it also means food sits in your stomach longer than your body is used to, which triggers nausea, bloating, and that uncomfortable “too full” feeling even after small meals.
The nausea is typically worst during the first few weeks and when your dose increases. Ozempic is prescribed on a gradual schedule, starting at a low dose and stepping up over months, specifically to give your body time to adjust. For many people, the nausea fades or becomes manageable within a few weeks at each new dose. For others, it persists and can be accompanied by vomiting, diarrhea, or constipation.
Foods That Make It Worse
Because your stomach is emptying more slowly on Ozempic, what you eat matters more than usual. High-fat foods like pizza, fried chicken, and doughnuts are some of the worst offenders. Fat already takes longer to digest, and when combined with the drug’s effects, greasy meals can sit in your stomach and intensify nausea, vomiting, and heartburn.
Other common triggers include spicy foods, sugary drinks, refined carbohydrates like white bread and crackers, and processed snacks. Smaller, more frequent meals that emphasize lean protein and vegetables tend to be much easier to tolerate. This isn’t just about comfort. Persistent vomiting and diarrhea can lead to dehydration, which opens the door to more serious complications.
When Slow Digestion Becomes Gastroparesis
In a small number of people, Ozempic’s effect on stomach emptying goes beyond temporary discomfort and crosses into a condition called gastroparesis, where the stomach essentially stops moving food through at a normal pace. Gastroparesis causes persistent upper abdominal pain, bloating, nausea, and feeling full almost immediately after eating.
A study published in JAMA found that people using GLP-1 drugs like Ozempic for weight loss had roughly 3.7 times the risk of developing gastroparesis compared to people on a different weight loss medication. The overall number of cases was still small, but the condition can be difficult to manage and may not always resolve quickly after stopping the drug. The exact prevalence of semaglutide-induced gastroparesis is still unknown.
Gallbladder Problems
Rapid weight loss from any cause raises the risk of gallstones, and Ozempic adds its own layer of risk on top of that. A large analysis pooling data from 76 clinical trials found that people taking GLP-1 drugs had a 37% higher risk of developing gallbladder disease compared to those not on the medications. A separate pharmacovigilance analysis looking specifically at semaglutide found an even stronger signal, with roughly four to six times the expected rate of gallstones and gallbladder inflammation in reported cases.
Gallstones can be painless, but when they cause problems, they typically show up as sudden, intense pain in the upper right abdomen, often after eating. Some people develop inflammation of the gallbladder that requires surgery. If you notice sharp abdominal pain that doesn’t match the usual GI discomfort from Ozempic, that’s worth getting checked promptly.
Kidney Injury From Dehydration
Ozempic doesn’t directly damage the kidneys, but severe nausea, vomiting, and diarrhea can cause dehydration, and dehydration can lead to acute kidney injury. Case reports have documented kidney problems in patients on semaglutide, and in some cases the damage was serious enough to require dialysis. The pattern is consistent: GI symptoms lead to fluid loss, which stresses the kidneys.
This risk is highest in people who already have reduced kidney function or who aren’t replacing fluids adequately. Staying well-hydrated is particularly important during the early weeks of treatment and during dose increases, when nausea tends to be at its worst.
Muscle Loss Alongside Fat Loss
Any significant weight loss, whether from medication, surgery, or diet, involves losing some muscle along with fat. With Ozempic, studies show the ratio is roughly three times more fat lost than lean mass. In one year-long study, patients lost about 19% of their total fat mass but also lost around 3 kilograms (about 6.6 pounds) of lean mass in the first seven months. The encouraging finding was that lean mass stabilized after that point even as fat loss continued.
Still, losing muscle matters, especially for older adults or people who were already sedentary. Muscle loss can affect metabolism, balance, and overall strength. Resistance training and adequate protein intake during treatment help preserve lean mass, and this is something worth planning for rather than discovering after the fact.
Pancreatitis and Bowel Obstruction
Acute pancreatitis, an inflammation of the pancreas that causes severe abdominal pain, has been reported in people taking Ozempic. The JAMA study also found an elevated risk of bowel obstruction among GLP-1 drug users. Both are uncommon but serious. Pancreatitis typically presents as intense pain in the upper abdomen that radiates to the back, often with nausea and vomiting that feel distinctly different from the usual GI side effects.
The Thyroid Warning on Every Box
Ozempic carries the FDA’s most serious label warning, a boxed warning, about the risk of thyroid tumors. In two-year studies, both mice and rats developed thyroid C-cell tumors at doses comparable to what humans take. Rats showed a statistically significant increase in cancerous thyroid tumors at exposures as low as one-fifth of the maximum recommended human dose.
Whether this translates to humans is genuinely unknown. The FDA label states plainly that “human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.” Out of caution, Ozempic is completely off-limits for anyone with a personal or family history of medullary thyroid carcinoma or a genetic condition called Multiple Endocrine Neoplasia syndrome type 2. Symptoms to be aware of include a lump in the neck, difficulty swallowing, trouble breathing, or persistent hoarseness.